We are live on ! Find out more
TXG icon

10x Genomics

317 hedge funds and large institutions have $1.44B invested in 10x Genomics in 2025 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 98 increasing their positions, 91 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more call options, than puts

Call options by funds: $5.96M | Put options by funds: $2.8M

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

57% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 42

7% more funds holding

Funds holding: 297317 (+20)

8% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 91

1% more capital invested

Capital invested by funds: $1.42B → $1.44B (+$16.6M)

2.94% less ownership

Funds ownership: 110.37%107.43% (-2.9%)

Holders
317
Holders Change
+20
Holders Change %
+6.73%
% of All Funds
4.16%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
66
Increased
98
Reduced
91
Closed
42
Calls
$5.96M
Puts
$2.8M
Net Calls
+$3.16M
Net Calls Change
+$1.32M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$155M +$10.9M +834,272 +7%
AIM
2
ARK Investment Management
Florida
$139M -$26.1M -2,004,707 -14%
BlackRock
3
BlackRock
New York
$111M +$334K +25,613 +0.3%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$98.9M -$7.02M -538,403 -6%
Millennium Management
5
Millennium Management
New York
$63.6M +$33.3M +2,554,142 +89%
Sumitomo Mitsui Trust Group
6
Sumitomo Mitsui Trust Group
Japan
$62.9M -$8.3M -636,744 -11%
NAMA
7
Nikko Asset Management Americas
New York
$62.9M -$8.25M -632,770 -11%
Wellington Management Group
8
Wellington Management Group
Massachusetts
$50.1M +$31.2M +2,394,355 +127%
QCM
9
Quantinno Capital Management
New York
$40.8M +$16.4M +1,258,933 +56%
Bank of America
10
Bank of America
North Carolina
$39.9M +$5.08M +389,797 +13%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$34.5M +$7.17M +550,250 +23%
Morgan Stanley
12
Morgan Stanley
New York
$32.9M -$8.73M -669,713 -19%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$31.7M +$788K +60,424 +2%
AQR Capital Management
14
AQR Capital Management
Connecticut
$31.5M -$18.4M -1,410,809 -34%
Goldman Sachs
15
Goldman Sachs
New York
$31.3M +$27M +2,067,562 +340%
State Street
16
State Street
Massachusetts
$29.5M +$359K +27,523 +1%
Capital World Investors
17
Capital World Investors
California
$17M
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$16.7M +$16M +1,223,602 +594%
T. Rowe Price Investment Management
19
T. Rowe Price Investment Management
Maryland
$15.7M +$4.76M +364,738 +37%
Voloridge Investment Management
20
Voloridge Investment Management
Florida
$15.4M -$2.68M -205,636 -13%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$14M -$8.01M -614,700 -34%
Charles Schwab
22
Charles Schwab
California
$13.4M +$3.14M +240,851 +27%
JP Morgan Chase
23
JP Morgan Chase
New York
$12.6M +$12.4M +951,495 +778%
Renaissance Technologies
24
Renaissance Technologies
New York
$12.2M -$5.57M -427,334 -29%
Northern Trust
25
Northern Trust
Illinois
$12.1M +$391K +29,951 +3%

TXG Hedge Fund Activity: Q3 2025 in Review

317 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2025, worth a combined $1.44B — up 1.2% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new TXG positions and 42 closed out — a net gain of 24 holders — while 98 added to existing stakes and 91 trimmed.

The largest buyer was Millennium Management, adding an estimated $33.3M. The largest seller was ARK Investment Management, cutting an estimated $26.1M.

  • 317 institutional investors held 10x Genomics (TXG) as of Q3 2025, up from 297 in Q2 2025.
  • Funds reported $1.44B of 10x Genomics stock for Q3 2025, up 1.2% quarter-over-quarter.
  • 66 funds opened new 10x Genomics positions in Q3 2025 and 42 closed out, a net change of +24 holders.
  • The largest 10x Genomics buyer in Q3 2025 was Millennium Management, an estimated $33.3M added.
  • The largest 10x Genomics seller in Q3 2025 was ARK Investment Management, an estimated $26.1M sold.

Based on aggregated 13F filings for Q3 2025.